In an interview with Medtech Insight, Dexcom’s COO Jake Leach and Adrian Gut, senior director international access, discuss the company’s global expansion, the role of AI in diabetes management, the challenges of securing reimbursement, and how regulators are influencing the future of CGM technology.
In this in-depth conversation, they discuss the challenges of expanding Dexcom’s global footprint, the company’s reimbursement strategy, and the evolving role of regulators in fostering innovation.
Key Takeaways
While countries like France offer full reimbursement for CGM users, many healthcare systems still lag. Dexcom is working with policymakers, clinicians, and advocacy groups to expand coverage globally.
Continuous glucose monitoring (CGM) technology has transformed diabetes management, enabling real-time tracking of glucose levels and empowering individuals to make informed health decisions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
It’s no secret that Marty Makary and Robert F. Kennedy Jr. have a different take on user fees, with Makary viewing them as a funding necessity and Kennedy as a corrupting influence. But will they find a way to strike a balance during the next MDUFA reauthorization talks so each can claim victory?
Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.
Volta Medical received a labeling expansion for its AF-Xplorer mapping software to treat A-fib, which provides the clinical evidence needed to broaden US access. The company hopes for FDA clearance for its improved second-gen AF-Xplorer II software.
In this in-depth interview with Medtech Insight, Pavan Choudary unpacks the implications of recent free trade agreements (FTAs) such as India’s with the UK, the potential fallout from new US tariffs on Indian device exports, and the pressing need for regulatory harmonization.
The UK's regulatory agency is the first to join a new international network for oversight of AI in healthcare run by a non-profit organization, HealthAI, the global agency for responsible AI in health.
Volta Medical received a labeling expansion for its AF-Xplorer mapping software to treat A-fib, which provides the clinical evidence needed to broaden US access. The company hopes for FDA clearance for its improved second-gen AF-Xplorer II software.
The Modern Industrial Strategy is the first of this summer’s UK blueprints for supporting life sciences industrial activity and transforming NHS healthcare delivery. The UK market must also benefit from its own innovation activity, says industry.
